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IL1B-CGTC haplotype is associated 
with colorectal cancer in admixed 
individuals with increased African 
ancestry
María Carolina Sanabria-Salas1,2, Gustavo Hernández-Suárez1, Adriana Umaña-Pérez2,  
Konrad Rawlik3, Albert Tenesa3,4, Martha Lucía Serrano-López1,2, Myriam Sánchez de Gómez2, 
Martha Patricia Rojas1, Luis Eduardo Bravo5, Rosario Albis6, José Luis Plata7, 
Heather Green8, Theodor Borgovan8, Li Li9, Sumana Majumdar9, Jone Garai9, Edward Lee10, 
Hassan Ashktorab10, Hassan Brim10, Li Li8, David Margolin8, Laura Fejerman11 & 
Jovanny Zabaleta9,12
Single-nucleotide polymorphisms (SNPs) in cytokine genes can affect gene expression and thereby 
modulate inflammation and carcinogenesis. However, the data on the association between SNPs in 
the interleukin 1 beta gene (IL1B) and colorectal cancer (CRC) are conflicting. We found an association 
between a 4-SNP haplotype block of the IL1B (-3737C/-1464G/-511T/-31C) and CRC risk, and this 
association was exclusively observed in individuals with a higher proportion of African ancestry, such 
as individuals from the Coastal Colombian region (odds ratio, OR 2.06; 95% CI 1.31–3.25; p < 0.01). 
Moreover, a significant interaction between this CRC risk haplotype and local African ancestry dosage 
was identified in locus 2q14 (p = 0.03). We conclude that Colombian individuals with high African 
ancestry proportions at locus 2q14 harbour more IL1B-CGTC copies and are consequently at an 
increased risk of CRC. This haplotype has been previously found to increase the IL1B promoter activity 
and is the most frequent haplotype in African Americans. Despite of limitations in the number of 
samples and the lack of functional analysis to examine the effect of these haplotypes on CRC cell lines, 
our results suggest that inflammation and ethnicity play a major role in the modulation of CRC risk.
Colorectal cancer (CRC) is considered a major public health problem and is the fourth most common can-
cer and the fifth leading cause of cancer-related death in both sexes worldwide1. Thus, studies of the effects of 
non-genetic2,3 and genetic risk factors on CRC development4 have important implications for understanding the 
aetiology of this disease.
Inflammation is a hallmark of cancer5 and has been particularly associated with genetic instability and stromal 
mechanisms that affect the CRC tumour microenvironment, including angiogenesis, invasion and metastasis6. 
Specifically, interleukin 1 beta protein (IL-1 beta) plays a critical role as a pro-inflammatory cytokine in colon 
inflammation and carcinogenesis7 by up-regulating cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) via 
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several signalling pathways8,9; furthermore, SNPs within the promoter region of the gene can modulate the IL-1 
beta levels and this modulation depends upon the haplotype context10. However, the frequencies of these haplo-
types vary by population10, which may partly explain the disparities observed in CRC incidence between African 
Americans and U.S. Non-Hispanic Whites11,12.
A heterogeneous risk pattern for CRC mortality across Colombian populations has been reported13, and this 
pattern could be explained by the influence of environmental and genetic factors13, including genetic ancestry. 
The latter is supported by the fact that Colombian populations are characterized by different three-way admixture 
contributions from ancestral source populations; for instance, the proportions of African ancestry are higher 
across cities near the Coastal compared to those located within the Andean region14,15. Moreover, African ances-
try was previously shown to be associated with increased risk of CRC in individuals from Colombia16.
Previous genetic studies of admixed individuals have identified DNA markers linked to genetic ancestry that 
are associated with the risk of various types of cancer, and these markers partly explain the disparities in health 
between some populations groups17–21. Because recombination events can change allele and haplotype frequen-
cies among populations, especially in cases of admixture between different ethnic groups22,23, and because the 
data on the effects of IL1B variants on cancer risk differ by study population24–29, we took advantage of the charac-
teristic variation in the genetic structure of our admixed samples to identify the associations between adenoma-
tous polyps (AP) as well as CRC risk with IL1B haplotypes and their interactions with global and local ancestry 
proportions in Colombians; we also analysed the variations in these effects by region. To the best of our knowl-
edge, this study is the first to explore the association of IL1B haplotypes with AP and CRC risk in a genetically 
admixed population.
Results
Participants’ characteristics. Descriptive characteristics for three groups of participants, AP, CRC and 
controls, from the Andean and Coastal Colombian regions are summarized in Supplementary Table S1. The AP 
and CRC groups contained more subjects within the age range of 50 to 69 years compared to controls (68.6%, 
63.8% and 45.8%, respectively; p < 0.01). In addition, compared to controls, the proportion of male subjects was 
higher in the CRC group (42.4% and 50.7%, respectively; p = 0.03), and a larger percentage of the AP group had 
a college degree or a higher education level (14.6% and 24.1%, respectively; p = 0.03), whereas more patients with 
CRC had no education or only completed primary school (34.7% and 51%, respectively; p < 0.01). The family 
history of CRC in immediate relatives, NSAID consumption or region of origin did not differ between groups.
Differences in the allele, genotype and haplotype frequencies of IL1B SNPs by case-control 
status. We selected five IL1B SNPs for which conflicting results regarding their association with inflammation 
and neoplastic processes had been published in previous studies24–29; four of these SNPs are located within the 
promoter region (− 3737 C > T, − 1464 G > C, − 511C > T and − 31 T > C), and the fifth is located in the coding 
region (+ 3954 C > T). In single SNP analyses we found that IL1B-1464CC individuals (versus CG + GG) were 
protected from AP but not CRC (p = 0.04). No other associations were observed (Supplementary Table S2).
Given the high linkage disequilibrium (LD) between the SNPs included in the analysis and due to previous 
work investigating haplotypes of IL1B in other populations10, we obtained haplotypes for this region based on 
the 5 genotyped SNPs. The four SNPs located in the promoter region of the IL1B gene are in strong LD and form 
one haplotype block (Supplementary Fig. S1). Within this haplotype block, only five of 16 possible IL1B promoter 
haplotypes were found with a frequency greater than 0.01 (Table 1). Because the IL1B-CCTC haplotype (N°4) was 
the most frequent haplotype in our admixed sample (41%) (Table 1), it was used as the reference in all analyses. 
According to the unadjusted general lineal model (GLM) analysis, the haplotype IL1B-CGTC (N°3) was associ-
ated with an increased risk of CRC (odds ratio, OR 1.39; 95% CI 1.02–1.90; p = 0.03) (Table 1). In the conditional 
haplotype tests controlling for the IL1B-511/IL1B-31 SNPs, we confirmed that the IL1B-1464G allele (haplotype 
N°3) was a risk factor for CRC compared to having the IL1B-1464C allele (haplotype N°4) (subnull p = 0.04; like-
lihood ratio test: chi-square = 5.63, Degrees of freedom (df ) = 2, p = 0.06). This result was concordant with the 
independent effect of IL1B-1464 test (likelihood ratio test: chi-square = 4.38, df = 1, p = 0.04) (Table 1).
IL1B Haplotypes
Total (n = 997) 
Frequency
Controls 
(n = 500) 
Frequency
Adenomatous Polyps (AP) (n = 191) Colorectal Cancer (CRC) (n = 306)
N° −3737 −1464 −511 −31 Frequency OR [95% CI] p value Frequency OR [95% CI] p value
1 C G C T 0.124 0.130 0.134 1.14 [0.78–1.65] 0.86 0.109 0.88 [0.63–1.24] 0.22
2 C G C C 0.011 0.011 0.010 1.09 [0.36–3.26] 0.94 0.011 1.08 [0.43–2.71] 0.94
3* C G T C 0.127 0.116 0.115 1.10 [0.74–1.64] 0.97 0.154 1.39 [1.02–1.90] 0.03
4* C C T C 0.410 0.425 0.385 1 ref ref 0.400 1 ref ref
5 T G C T 0.327 0.317 0.356 1.26 [0.95–1.67] 0.16 0.325 1.08 [0.85–1.37] 0.73
Table 1.  IL1B haplotypes and their association with AP and CRC risk in Colombian samples. P values 
for the unadjusted GLM analysis to evaluate the effect of IL1B haplotypes on AP and CRC risk among 997 
Colombian samples. *The difference in CRC risk was significant (subnull p = 0.04) between IL1B-1464C allele 
carriers and IL1B-1464G allele carriers in a conditional haplotype test (controlling for the IL1B-511/IL1B-31 
SNPs) and when testing for IL1B-1464 independent effects (likelihood ratio test: chi-square = 4.38, df = 1, 
p = 0.04). df, degrees of freedom.
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Genetic structure and global ancestry estimations. We were able to perform Multidimensional 
Scaling analyses (MDS) and global ancestry estimations in Colombian samples genotyped with genome-wide 
and candidate-gene platforms (Supplementary Methods). In both sets, cases and controls from Colombia 
overlapped, and most of them scattered between the European and Amerindian/Asian reference populations 
but were more closely related to Europeans; in addition, a small subset of them were close to the Africans 
(Supplementary Fig. S2). Global ancestry proportions per individual calculated with ADMIXTURE30 are shown 
in Supplementary Fig. S2. Regarding these estimates, European, Amerindian and African ancestry proportions 
for genome-wide and candidate-gene sets were strongly correlated for 85 samples genotyped using both plat-
forms, despite the use of different reference populations and numbers of SNPs in each case (Pearson’s correla-
tion coefficients of 0.77, 0.76 and 0.87 for each component, respectively) (Fig. 1C). We also identified a strong 
correlation between ancestry proportions estimated using two different statistical approaches, i.e., RFMix31 and 
ADMIXTURE30, in the 393 samples with genome-wide genotypes (0.94, 0.92 and 0.99 for European, Amerindian 
and African components, respectively) (Fig. 1C).
Due to the right-skewed distribution of the African ancestry proportions in our admixed samples, we selected 
a non-parametric test to assess differences in global ancestry estimates among Colombian cases and controls 
(Fig. 1). We found significant differences in the European and Amerindian ancestry proportions between the 
AP and control groups for both sets of individuals (genome-wide set: p values < 0.01 for both components; 
candidate-gene set: p values of 0.04 and < 0.01, respectively) (Fig. 1A,B). Moreover, the African ancestry pro-
portions significantly differed between the CRC group and the control group for genome-wide samples only 
(p = 0.04) (Fig. 1A).
IL1B haplotype association with AP and CRC risk adjusted for global ancestry. Among the 791 
samples with both IL1B haplotype information and global ancestry estimations, we tested different multinomial 
logistic regression analyses that model phenotypes by global ancestry proportions (Supplementary Table S3). 
The best and least complex model according to the Akaike Information Criterion (AIC) was model 13, which 
included European and African ancestries along with array, sex, age, educational level and NSAID consump-
tion (Supplementary Table S3.1). According to this model, European ancestry was only associated with AP risk 
(OR 1.98; 95% CI 1.35–2.91; p < 0.01), whereas African ancestry was associated with both AP (OR 1.12; 95% CI 
Figure 1. Differences in global ancestry proportions between cases and controls for genome-wide and 
candidate-gene genotyped samples (P values for the Wilcoxon rank sum Test are displayed). (A) Ancestry 
estimations per group for the genome-wide set. The difference in ancestries between the AP and control groups 
was significant for the European and Amerindian components (p < 0.01) and between the CRC and control 
groups for the African proportion (p = 0.04). (B) Ancestry estimations per group for the candidate-gene set.  
The difference in ancestries between the AP and control groups was significant for the European and 
Amerindian components (p = 0.04 and < 0.01, respectively), whereas the African proportion did not 
significantly differ between the CRC and control groups within these candidate-gene sample sets. (C) Pearson’s 
correlation per ancestry component. The correlations between genome-wide genotyped samples obtained with 
RFMix and ADMIXTURE are for 393 Colombians. The correlations between genome-wide and candidate-
gene sets obtained with ADMIXTURE are for 85 overlapping samples. 1k-HGDP, 1000 genomes plus Human 
Genome Diversity Project databases; EUR - AME - AFR corresponds to global European, Amerindian and 
African components; AP, adenomatous polyps; CRC, colorectal cancer.
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1.03–1.22; p = 0.01) and CRC risk (OR 1.10; 95% CI 1.03–1.18; p = 0.01). Some of the AP and CRC risk was also 
explained by age, educational level and NSAID consumption (Supplementary Table S3).
Results from the unadjusted and adjusted GLM analyses to evaluate the effect of IL1B haplotypes on AP and 
CRC risk among these 791 Colombian samples are shown in Table 2. We found that haplotype IL1B-TGCT (N°5) 
was associated with an increased risk of AP in the unadjusted (OR 1.45; 95% CI 1.05–2.00; p = 0.02) and adjusted 
model (OR 1.40; 95% CI 0.98–2.00; p = 0.06) (Table 2). Furthermore, the association of the IL1B-CGTC (N°3) 
haplotype and CRC risk remained in both the unadjusted (OR 1.55; 95% CI 1.09–2.20; p = 0.02) and the adjusted 
model (OR 1.46; 95% CI 0.99–2.14; p = 0.06) (Table 2).
To identify differences in the effect of these haplotypes on the AP and CRC risk for each Colombian region, 
we used the same stratification method as that described in Supplementary Fig. S3. The latter showed that peo-
ple from the Coast have higher African ancestry than those from the Andean region of the country. In this 
analysis, we saw a trend in the association of the IL1B-TGCT (N°5) haplotype with AP in both regions, Andean 
(95% CI 0.96–2.40) and Coastal (95% CI 0.93–2.49) (Table 3). Interestingly, we found that the association between 
the IL1B-CGTC (N°3) haplotype and CRC risk was exclusive to Colombians from the Coast (OR 2.06; 95% CI 
1.31–3.25; p < 0.01) (Table 3).
IL1B haplotype frequencies among self-reported African American CRC cases and reference 
populations. The IL1B-CGTC (N°3) haplotype found to be associated with an increased risk of CRC in 
Colombian subjects from the Coastal region was also the most frequent haplotype in the self-reported African 
American CRC cases from this study and the African Americans from the Atherosclerosis Risk Communities 
Cohort (ARIC)10 (Supplementary Table S4). In addition, this haplotype was the least frequent haplotype in 
Non-Hispanic White populations from the US10. We used information available on HapMap332 via Haploview33, 
including a simplified haplotype configuration (with IL1B-511 and IL1B-31 SNPs) and found similarities in 
IL1B gene 
haplotypes Total (n = 791) 
Frequency
Controls 
(n = 343) 
Frequency
Adenomatous Polyps (AP) (n = 163) Colorectal Cancer (CRC) (n = 285)
Frequency
Unadjusted Model Adjusted Model
Frequency
Unadjusted Model Adjusted Model
N° (ID)10 OR [95% CI] p value OR [95% CI] p value OR [95% CI] p value OR [95% CI] p value
1 (a) CGCT 0.125 0.140 0.126 1.02 [0.67–1.54] 0.94 0.90 [0.57–1.41] 0.65 0.107 0.79 [0.55–1.14] 0.21 0.76 [0.52–1.11] 0.16
2 — CGCC 0.013 0.016 0.009 0.72 [0.21–2.49] 0.61 0.91 [0.25–3.33] 0.88 0.012 0.79 [0.31–2.01] 0.62 0.61 [0.23–1.61] 0.32
3 (c) CGTC 0.124 0.105 0.107 1.19 [0.74–1.92] 0.47 1.35 [0.79–2.30] 0.28 0.156 1.55 [1.09–2.20] 0.02 1.46 [0.99–2.14] 0.06
4 (d) CCTC 0.409 0.426 0.374 1 ref ref 1 ref ref 0.409 1 ref ref 1 ref ref
5 (b) TGCT 0.328 0.312 0.383 1.45 [1.05–2.00] 0.02 1.40 [0.98–2.00] 0.06 0.316 1.05 [0.80–1.36] 0.74 1.02 [0.77–1.34] 0.90
Table 2.  Association of IL1B haplotypes with AP and CRC risk adjusting for global ancestry and other 
covariates in Colombian samples. P values for the unadjusted and adjusted GLM analyses to evaluate the effect 
of IL1B haplotypes on AP and CRC risk among 791 Colombian samples with available global ancestry estimates 
and IL1B haplotype information. Within the adjusted models, the OR shows the effect of each haplotype on AP 
and CRC risk compared to controls after controlling for many covariates, such as sex, age, educational level, 
global ancestry estimations and array (candidate-gene or genome-wide). According to the anova.haplo.glm() 
test, including NSAID consumption did not add more information to the model (p > 0.05).
IL1B gene 
haplotypes by region N°
Total (n = 791) 
Frequency
Controls Adenomatous Polyps (AP) Colorectal Cancer (CRC)
Frequency Frequency OR [95% CI] p value Frequency OR [95% CI] p value
Andean
(n = 367) (n = 163) (n = 79) (n = 125)
CGCT 1 0.125 0.138 0.127 0.94 [0.51–1.73] 0.83 0.108 0.70 [0.40–1.22] 0.21
CGTC 3 0.067 0.067 0.070 1.31 [0.56–3.06] 0.53 0.064 0.91 [0.45–1.86] 0.80
CCTC 4 0.459 0.463 0.405 1 ref ref 0.488 1 ref ref
TGCT 5 0.346 0.328 0.399 1.52 [0.96–2.40] 0.08 0.336 0.98 [0.68–1.42] 0.92
Coastal
(n = 424) (n = 180) (n = 84) (n = 160)
CGCT 1 0.125 0.142 0.125 0.98 [0.54–1.79] 0.95 0.106 0.93 [0.56–1.55] 0.79
CGCC 2 0.022 0.028 0.018 0.93 [0.24–3.62] 0.91 0.019 0.81 [0.29–2.28] 0.69
CGTC 3 0.173 0.139 0.143 1.23 [0.65–2.32] 0.52 0.228 2.06 [1.31–3.25] <0.01
CCTC 4 0.366 0.392 0.345 1 ref ref 0.347 1 ref ref
TGCT 5 0.312 0.297 0.369 1.52 [0.93–2.49] 0.10 0.300 1.14 [0.77–1.69] 0.52
Table 3.  Association between IL1B haplotypes and AP or CRC risk among Colombians stratified by region 
of origin. P values for the adjusted GLM analyses to evaluate the effect of IL1B haplotypes on AP and CRC risk 
stratified by region of origin. OR shows the effect of IL1B haplotypes on AP and CRC risk adjusted for sex, age 
and educational level.
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the haplotype frequencies between the Colombian control group, HapMap3 African Americans32 and African 
Americans from the ARIC study10 (Supplementary Table S5).
Role of locus-specific ancestry and IL1B risk haplotypes on CRC and AP. The association of IL1B 
haplotypes and locus-specific ancestry with the risk of AP and CRC were analysed using only the 393 Colombian 
samples for which the aforementioned information was available; these samples represented only 50% of the 791 
sample used previously in the adjusted regression analyses. We saw great variations in the level of excess of local 
African and European ancestries per marker in chromosome 2 for the CRC and AP groups relative to the control 
group (Supplementary Fig. S4), and the corresponding −log10 (P-values) obtained for these differences in the 
GLM analyses adjusted by sex, age, educational level and global ancestries are shown in Fig. 2.
Interestingly, the 18 SNPs located in the selected 2q14 region exhibited the largest differences in African ances-
try dosage between the CRC group and the control group (overlapped green dots, p = 6.58 × 10−4; false discovery 
rate, FDR, corrected p = 0.09) (Fig. 2A); although these differences are significant at a nominal level, after correc-
tion for multiple testing the association is not significant at the 5% level but it is suggestive (p < 0.1).
To better understand this result, we plotted each ancestry dosage within the 2q14 region by phenotype and 
found that the CRC group contains a higher proportion of African ancestry dosage (1 or 2 copies) than the AP 
and control groups (Fig. 3A). Moreover, 50% of the CRC samples with two copies of African ancestry carried two 
copies of the IL1B-CGTC haplotype, and the remaining 50% carried at least one copy (Fig. 3C).
Table 4 shows the multinomial logistic regressions conducted to evaluate the effect of global and locus-specific 
African ancestry on the risk of CRC, including the IL1B-CGTC haplotype copies, adjusted by sex, age, educational 
level, NSAID consumption and family history of CRC. We found that both global and locus-specific African 
ancestries were individually associated with an increased risk of CRC (Model 1a and 2a, respectively). When we 
included the main effects of both variables in the same model, the association with CRC remained significant only 
for locus-specific African ancestry (OR 3.40; 95% CI 1.05–10.98; p = 0.04; Model 3a). Although we found that 
the IL1B-CGTC haplotype was associated with CRC risk in Colombians, especially individuals from the Coastal 
region characterized by having a higher African ancestry, our results for this small set of 393 individuals only sug-
gests this association (95% CI 0.88–2.82; Model 4a). Remarkably, the interaction of IL1B-CGTC haplotype copies 
with locus-specific African ancestry was associated with CRC (p = 0.03; Model 6a); nevertheless, when testing 
only the main effects of all three variables, only locus-specific African ancestry was found to be associated with 
CRC (OR 3.58; 95% CI 0.97–13.30; p = 0.06; Model 7a).
Figure 2. Manhattan plots of the −log10 (P-values) from adjusted GLM analyses that model phenotypes 
by local ancestry dosage per marker along chromosome 2. (A) Plot of the differences in local African ancestry 
copies between the CRC and control groups. Green overlapping dots are SNPs within the 2q14 region, which 
holds the IL1B gene (FDR corrected p = 0.09). (B) Plot of the differences in local European ancestry copies 
between the AP and control groups. Green overlapping dots are the SNPs in the 2q14 region. CRC, colorectal 
cancer; AP, adenomatous polyps; FDR, false discovery rate.
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For European ancestry dosage, none of the comparisons revealed significant differences or suggestive p values 
in the adjusted GLM analysis between the AP and control groups after correction for multiple testing, including 
locus 2q14 (overlapped green dots; Fig. 2B). These results are consistent with those displayed in Fig. 3B, which 
shows the excess or defect of each locus-specific ancestry within locus 2q14 with respect to the average of each 
ancestry along chromosome 2.
We also used adjusted multinomial logistic regressions to evaluate AP risk, including global and locus-specific 
European ancestry, and copies of the IL1B-TGCT haplotype (Table 4). We found that AP risk was mainly 
explained by the effect of global European ancestry (OR 1.91; 95% CI 1.17–3.13; p = 0.01; Model 7b) and that the 
data suggested an association with AP risk for the IL1B-TGCT haplotype copies (95% CI 0.83–2.66; Model 4b). 
As already observed in the multimarker regression analysis for AP (Fig. 2B), the European ancestry proportion in 
2q14 does not play an important role in AP risk (Model 7b, Table 4).
Discussion
We found that AP is less common among recessive carriers of the IL1B-1464C allele. Furthermore, the risk of 
CRC significantly differed between carriers of the IL1B-1464G allele and the IL1B-1464C allele, when considering 
the haplotype context (N°3 versus N°4). Our results and the literature support the potential effect of this variant 
in preventing neoplastic changes in some tissues because the IL1B-1464G/C SNP flanks a putative binding site 
for the proteins DBP, C/EBP alpha and Pit-1a, and the C allele shows a lower transcriptional activity in haplotype 
context with IL1B-511T and IL1B-31C10,34. Therefore, accounting for haplotype context is important in associa-
tion studies.
Although increased IL-1 beta production has also been reported for other SNPs in the promoter region of the 
IL1B gene10,34–37, associations of these SNPs with cancer are variable and depend on the cancer model and genetic 
background of the population24–29. These inconsistencies are likely related to a small effect or the low frequency 
of these variants in some of the studied populations, which makes the identification of any association with the 
disease of interest difficult. Our three-way admixed population provides an opportunity to test differences in the 
effect of IL1B haplotypes among individuals with varying degrees of admixture. Regarding these analyses, we 
found that the second most frequent haplotype in Colombian controls, IL1B-TGCT, was associated with AP risk 
irrespective of the region of origin. Also, our results suggest that most of the AP risk can be attributed to global 
Figure 3. Ancestry dosage and IL1B-CGTC haplotype copies in Colombian samples by phenotype.  
(A) Ancestry dosage in Colombian samples by phenotype. This analysis included 393 samples with available 
locus ancestry estimates. An ancestry dosage of 0, 1 or 2 corresponds to the number of specific ancestry copies 
in the selected 100000-bp region at locus 2q14 (Chr2:113500000:113600000) that contains the IL1B gene. 
(B) Local ancestry proportions in locus 2q14 relative to the average locus-specific ancestry across all loci in 
chromosome 2 by phenotype. (C) Percentage of IL1B-CGTC haplotype copies (0, 1 or 2) within each local African 
ancestry dosage group (0, 1 or 2). CRC, colorectal cancer; AP, adenomatous polyps; Chr2, chromosome 2; EUR -  
AME - AFR, corresponds to European, Amerindian and African ancestries; Eur2q_chr2 - Ame2q_chr2 - Afr2q_chr2, 
corresponds to European, Amerindian or African locus specific ancestry minus their respective ancestry 
proportion for all of chromosome 2.
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European ancestry proportions instead of local European ancestry at 2q14, meaning that non-genetic factors 
associated with the European component could have an important role in the risk of AP. Further genome-wide 
association analysis taking into account other non-genetic risk factors could help disentangle the observed associ-
ation between AP risk and global European ancestry in Colombians. We did not find an effect of the IL1B-TGCT 
haplotype on CRC risk, which could be explained in part by the small sample size or the fact that this haplotype 
exhibits moderate transcriptional activity in vitro10, making it more suitable as a susceptibility marker of milder 
lesions that do not necessarily evolve to CRC.
CRC risk was consistently associated with the IL1B-CGTC haplotype in Colombians, especially in individuals 
from the Coastal region of the country, who exhibit the highest African ancestry proportions. Despite this result, 
an analysis of 393 individuals with local ancestry inference (LAI) data only suggested an effect of IL1B-CGTC 
on CRC risk; lack of significance for this association is likely due to the small sample size and the overall low 
frequency of this haplotype in Colombians (~13%). The important role of African ancestry within locus 2q14 
in CRC risk was suggested by the fact that variants within this region showed the lowest p-values in the multi-
marker regression analysis along chromosome 2. Interestingly, we found a significant interaction between the 
IL1B-CGTC haplotype and local African ancestry for CRC risk. Because only local African ancestry remained 
significantly associated with CRC risk when we tested the main effects of the risk haplotype as well as local and 
global African ancestries, we conclude that additional African-related variants that could explain the risk of CRC 
may be located within the selected 2q14 region, and fine-mapping methods will help to identify these variants.
The relationship of the IL1B-CGTC haplotype with CRC risk and African ancestry identified herein corrobo-
rates previous work showing that this haplotype exhibits the highest transcriptional activity amongst four other 
possible IL1B promoter haplotypes10 and that it is the most frequent haplotype in African Americans10. Therefore, 
further population case-control studies among Colombians with different African ancestry proportions, seeking 
differences in the expression levels of IL-1 beta and its targets (such as COX-2 and PGE2) in colorectal tissues and 
plasma samples will help prove their utility as susceptibility markers for the risk of CRC in the general popula-
tion. The identification of such markers will allow individuals who are at an increased risk to be offered effective 
measures to prevent this type of cancer. For example, according to the atlas of cancer mortality in Colombia pub-
lished in 201013, two of the cities included in this study from the Andean region, Bogotá DC and Bucaramanga, 
belong to two regions with 27% and 11% higher risks of CRC mortality, respectively, than the rest of the coun-
try. Moreover, whereas among the cities included from the Caribbean Coast and surrounding areas, Cartagena, 
Barranquilla and Santa Marta, the risk of CRC mortality is lower than in the general population, in Cali and its 
CRC risk modelled by African ancestry and the IL1B-CGTC  
haplotype
AP risk modelled by European ancestry and the IL1B-TGCT 
haplotype
 OR [95% CI] p value OR [95% CI] p value
Model 1a Model 1b
 Global AFR ancestry 1.19 [1.01–1.41] 0.04 Global EUR ancestry 2.03 [1.27–3.25] <0.01
Model 2a Model 2b
 Local AFR at 2q14 4.06 [1.49–11.03] 0.01 Local EUR at 2q14 1.91 [0.91–4.03] 0.09
Model 3a Model 3b
 Local AFR at 2q14 3.40 [1.05–10.98] 0.04 Local EUR at 2q14 1.33 [0.60–2.94] 0.48
 Global AFR ancestry 1.06 [0.87–1.30] 0.58 Global EUR ancestry 1.94 [1.18–3.17] 0.01
Model 4a Model 4b
 IL1B-CGTC 1.58 [0.88–2.82] 0.12 IL1B-TGCT 1.71 [0.99–2.96] 0.06
Model 5a Model 5b
 IL1B-CGTC 1.91 [0.69–5.27] 0.21 IL1B-TGCT 1.40 [0.79–2.48] 0.21
 Global AFR ancestry 1.10 [0.89–1.35] 0.40 Global EUR ancestry 1.57 [0.78–3.18] 0.21
 IL1B-CGTC: Global AFR ancestry 1.23 [0.81–1.85] 0.33 IL1B-TGCT: Global EUR ancestry 1.43 [0.55–3.74] 0.47
Model 6a Model 6b
 IL1B-CGTC 0.50 [0.19–1.28] 0.15 IL1B-TGCT 2.18 [0.71–6.66] 0.17
 Local AFR at 2q14 1.08 [0.19–6.07] 0.93 Local EUR at 2q14 2.12 [0.67–6.64] 0.20
 IL1B-CGTC: Local AFR at 2q14 15.68 [1.23–200.12] 0.03 IL1B-TGCT: Local EUR at 2q14 0.55 [0.11–2.69] 0.46
Model 7a Model 7b
 IL1B-CGTC 0.94 [0.46–1.92] 0.87 IL1B-TGCT 1.48 [0.83–2.66] 0.19
 Local AFR at 2q14 3.58 [0.97–13.30] 0.06 Local EUR at 2q14 1.13 [0.49–2.61] 0.77
 Global AFR ancestry 1.06 [0.87–1.30] 0.57 Global EUR ancestry 1.91 [1.17–3.13] 0.01
Table 4.  Association of ancestry proportions or IL1B risk haplotypes with CRC or AP risk. P values for the 
adjusted multinomial logistic regression analyses to evaluate the effect of African or European ancestry (global 
and/or locus-specific) on CRC and AP risk. These models also included the main effects and interactions with 
copies (0 versus 1 or 2) of the IL1B haplotypes of risk (IL1B-CGTC for CRC and IL1B-TGCT for AP risk). All 
models are adjusted for sex, age, educational level, NSAID consumption and a family history of CRC. AFR, 
African; EUR, European.
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surroundings in Valle del Cauca located in the Pacific Coast, the risk of CRC mortality is 22% higher than that in 
the rest of the country13. Interestingly, Cali has the highest concentration of Afro-Colombians38.
Overall, these results are of particular interest due to previous observations about disparities in CRC risk 
among different population groups, such as differences between Non-Hispanic White and African American 
U.S. populations, with respect to inflammatory diseases and cancer development11,39. Our findings highlight the 
importance of conducting genetic studies in admixed populations to reveal potential population-specific suscep-
tibility markers of risk for complex diseases.
Methods
Subjects. This is a multicentre, hospital-based case-control study that was conducted in six Colombian cities 
from the Andean (Bogotá and Bucaramanga) and Coastal regions (Cartagena, Santa Marta and Barranquilla in 
the Caribbean and Cali in the Pacific). These cities are characterized by differences in CRC mortality risk and 
ancestry proportions. A total of 306 CRC cases, 191 AP and 500 matched controls between age 30 and 74 years 
were enrolled. All cases were incident and confirmed by histopathology. The control group consisted of individ-
uals without gastrointestinal symptoms attending the outpatient services of primary care units. Neither cases nor 
controls had a personal history of other cancers, and neither group received chemotherapy or radiotherapy. Each 
participant provided written informed consent. This work was approved by the Ethics Committee of the Instituto 
Nacional de Cancerología, Bogotá, Colombia as a “study with greater than minimal risk” according to guidelines 
established in the document “RESOLUCIÓN 8430 DE 1993” for Ethical Aspects of Human Research, (Title II, 
Chapter 1) published by the República de Colombia Ministerio de Salud (https://www.invima.gov.co/images/pdf/
medicamentos/resoluciones/etica_res_8430_1993.pdf).
We also included samples from 177 self-reported African American patients with CRC diagnosed at the 
Howard University College of Medicine in Washington, D.C. and the Ochsner Clinic Foundation in New Orleans, 
LA for IL1B SNPs genotyping to compare the IL1B haplotype frequencies with those of Colombian samples. 
Because these samples were de-identified FFPE tissues and the study was retrospective, the LSUHSC IRB follow-
ing the recommendations for the use of human tissues and under strictest HIPAA protocols classified this specific 
study as an “Institutional Review Board (IRB) exempt” study.
All methods were performed in accordance with the declaration of Helsinki and local relevant guidelines and 
regulations, as already mentioned.
DNA extraction. DNA was extracted from 200 μ l of buffy coat using the QIAamp DNA Blood Mini Kit 
(QIAGEN, Valencia, CA, USA) according to the manufacturer’s protocol. The DNA was resuspended in 100 μ l of 
Ambion Nuclease-free Water (Ambion, Foster City, CA, USA) and stored at − 20 °C. DNA purity and concentra-
tion were assessed using a NanoDrop 2000 (Thermo Scientific, Wilmington, DE, USA).
IL1B SNPs genotyping. All subjects were genotyped for five IL1B SNPs using TaqMan SNP Genotyping 
Assays Kits (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s protocol. Four of these 
SNPs are located in the promoter region of the gene: − 3737 C > T (rs4848306), − 1464 G > C (rs1143623), 
511 C > T (rs16944) and − 31 T > C (rs1143627). The fifth SNP + 3954 C > T (rs1143634) is located within exon 
5. After PCR amplification, the genotype was determined using the Sequence Detection System (SDS) software 
(Applied Biosystems, Foster City, CA, USA). DNA controls with known genotype for each SNP were run in par-
allel. Hardy-Weinberg equilibrium for IL1B-genotyped SNPs was assessed using the exact test statistics PHWE in 
PLINK40,41. All IL1B SNPs were in Hardy-Weinberg equilibrium (p > 0.05) (data not shown).
Global ancestry estimation. We used two different platforms from Illumina® , a candidate-gene “Cancer 
SNP Panel” array that includes 1421 SNPs, and a genome-wide “Infinium® OmniExpressExome Array”, which 
includes 958178 SNPs, according to the manufacturer’s instructions, to genotype 521 and 443 Colombian sam-
ples, respectively.
Quality control (QC) and pruning steps were performed separately due to large differences in the num-
ber of markers tested within each array. These steps were based on the protocol described by Anderson 
et al.42 using PLINK v1.0740 and the R statistics v3.2.243 software, as recommended. All datasets were lifted 
over to the human genome build 37 coordinates as necessary. After QC steps for the candidate-gene data-
set (Supplementary Methods), a total of 1237 SNPs and 483 samples remained for further analysis. For 
genome-wide data, a total of 720815 SNPs and 415 samples remained for further analysis after QC procedures 
(Supplementary Methods).
We used the unsupervised model-based mode in ADMIXTURE30 for individual ancestry estimations 
using genotypes from autosomal markers and K = 3 ancestral populations individually for candidate-gene 
and genome-wide datasets. For candidate-gene data, reference populations from the HapMap3 project32 pub-
lic database were used (CEU = Utah residents of Northern and Western European ancestry; LWK = Luhya in 
Webuye, Kenya; and CHB = Han Chinese in Beijing, China; MEX = Mexican ancestry in Los Angeles, California) 
(Supplementary Methods). Because the allele frequencies are similar between Asians and Amerindians, we used 
the CHB reference population to discriminate the Amerindian component16,44. The final merged and pruned 
candidate-gene database used to infer global ancestry in 483 Colombian samples included 473 overlapping SNPs. 
For genome-wide data, we included the genotypes of reference populations from public databases, 1000 genomes45 
(IBS = Iberian Population in Spain and YRI = Yoruba in Ibadan, Nigeria) plus HGDP46 (AME = Amerindians, 
which includes Pima, Maya, Karitiana, Surui and Colombian Native Americans) (Supplementary Methods). The 
final merged and pruned genome-wide database used to infer global ancestry in 415 Colombian samples included 
9663 overlapping SNPs.
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After eliminating duplicates between both arrays (n = 85 samples) and selecting samples also genotyped 
for IL1B SNPs, a total of 791 Colombian samples with available global ancestry estimates remained for further 
adjusted regression analyses.
Local ancestry inference (LAI). Among all available methods for LAI47–51, we selected a discriminative 
approach supported by the RFMix v1.5.4 software31 because it performs an iterative analysis that, beginning with 
unadmixed panels, also utilizes information in the chromosomes of admixed individuals to infer local ancestry. 
This approach allows refining our knowledge of haplotype patterns in the ancestral populations and improves 
accuracy via expectation maximization (EM) steps31.
For the LAI procedures, we used a reference panel that included the same populations from 1000 genomes45 
and HGDP46 databases incorporated previously to calculate global ancestry proportions. Because RFMix31 
requires phased haplotypes input, we first phased genotypes from our genome-wide Colombian samples 
and HGDP46 data using 1000 genomes45 as a reference prior to the merging steps (Supplementary Methods). 
Specifically, we used the segmented haplotype estimation and imputation tool, SHAPEIT v2.77852, based on the 
modelling of stochastic processes through a Hidden Markov Model to phase genotypes. To correct for admixture 
in our reference populations, we performed five EM iterations, as recommended31.
Statistical analysis. A descriptive analysis based on the characteristics of the 997 Colombian samples gen-
otyped for the IL1B gene SNPs was performed in R43 using Pearson’s Chi-Squared Test to assess for differences 
among groups. Full model association tests between the disease and each SNP were performed in PLINK40. LD 
among all five IL1B SNPs was calculated using the Haploview algorithm33.
Global ancestry estimates from ADMIXTURE30 with candidate-gene or genome-wide datasets were obtained 
for 791 unique Colombian samples with IL1B haplotype information. Furthermore, the LAI results from RFMix31 
were used to calculate global ancestry as the average locus-specific ancestry across all loci for each individual 
with genome-wide data. Pearson’s correlation per ancestry component was computed between all estimates. 
Differences in ancestry proportions between the control and CRC or AP group were assessed with the Wilcoxon 
rank sum test for ancestry estimates obtained with ADMIXTURE30.
Because the sample size in this study is at best moderate and the observed African ancestry proportions were 
substantially skewed, we transformed the European and African ancestry components to a symmetric distribu-
tion using a logit transformation before conducting adjusted regression analyses. In these models, Amerindian 
ancestry was treated as the reference, and global ancestry proportions were always corrected by the “array” varia-
ble, referring to candidate-gene or genome-wide estimates.
Multinomial logistic regressions of phenotypes, including global ancestry estimates, sex, age, educational 
level, city of origin, NSAID consumption and a family history of CRC as explanatory covariates, were conducted 
with R43. The AIC was used to select the best model.
The IL1B haplotype frequencies among Colombian and African American CRC samples were inferred in R43, 
through EM computation of haplotype probabilities with progressive insertion of loci. Conditional haplotype 
tests were conducted in PLINK40 to evaluate differences in disease risk related to haplotype context when con-
trolling for some SNPs or when assessing for their independent effect. The odds ratio (OR) for each IL1B hap-
lotype and disease risk were obtained for Colombian samples using unadjusted and adjusted GLM in R43 while 
controlling for sex, age, educational level, global ancestry proportions and array variables. GLM analyses of IL1B 
haplotypes and disease risk were conducted in a stratified analysis by region of origin, using sex, age and educa-
tional level as covariates. In all cases, the most frequent haplotype was used as the reference, and rare haplotypes 
(less than 0.01) were not included in the analyses.
For the 393 Colombian samples with both IL1B haplotypes and LAI information, we estimated global ancestry 
for chromosome 2 as the average locus-specific ancestry across all loci. We also selected a 100000-bp region at 
locus 2q14 (Chr2:113500000:113600000; 18 SNPs; build 37) that holds the IL1B gene to calculate locus-specific 
ancestry. We plotted the variation of each ancestry proportion per marker in chromosome 2 in the CRC and AP 
groups relative to those in the control group used as the baseline and conducted a multimarker GLM analysis for 
CRC risk. Specifically, the African dosage per marker at chromosome 2 corrected for sex, age, educational level 
and global African ancestry was used as an explanatory variable. We conducted the same analysis comparing 
the AP and control groups but used the European dosage per marker at chromosome 2 and global European 
ancestry instead. Corresponding - log10 (P-values) for each analysis are displayed in Manhattan plots. The com-
puted P-values were adjusted for multiple comparisons using the FDR correction for 28579 test/variants along 
chromosome 2.
Finally, we performed multinomial logistic regression analyses that compared the respective IL1B risk hap-
lotypes copies and the effect of global and locus-specific African or European ancestry of the control group with 
those of the CRC and AP groups, and these comparisons were adjusted for sex, age, educational level, NSAID 
consumption and a family history of CRC.
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